Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temsirolimus + dexamethasone + mitoxantrone + vincristine + pegaspargase + methotrexate
- Development stage
- Discontinued
- Lead developer
- Children's Oncology Group
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral, Intrathecal
01
Overview
This combination therapy is an intensive re-induction chemotherapy regimen studied by the National Cancer Institute (NCI) and the Children's Oncology Group (COG) for pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The regimen utilizes a backbone of the UKALL R3 protocol—consisting of dexamethasone, mitoxantrone, vincristine, and pegaspargase—augmented with the mTOR inhibitor temsirolimus. Temsirolimus targets the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in lymphoid malignancies, to enhance the cytotoxic effects of the chemotherapy components. A Phase 1 dose-escalation study (ADVL1114) evaluated this combination but found that it resulted in excessive toxicity, including hypertriglyceridemia, mucositis, and sepsis, at all dose levels tested.
- Other names
- Temsirolimus and intensive re-induction therapyUKALL R3 with temsirolimus
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)mTOR (Mammalian target of rapamycin kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on temsirolimus + dexamethasone + mitoxantrone + vincristine + pegaspargase + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temsirolimus + dexamethasone + mitoxantrone + vincristine + pegaspargase + methotrexate.